Feb 19, 2018
BioGenerator-supported Company to Advance Cancer Therapies
ST. LOUIS – St. Louis-based startup Unleash Immuno Oncolytics, which has developed viral-based biologics to attack cancerous tumors, has attracted a major investment from publicly-traded Japanese company Oncolys BioPharma.
Unleash is an immunotherapy company that develops genetically-engineered adenoviruses to harness the immune system to fight cancer. While malignant tumors can trick the body’s immune system from attacking them, the Unleash viruses trigger the body’s immune system into action. By introducing a virus designed specifically to attack cancer, the virus invades the cancer cells, then unleashes the body’s ability to recognize and fight those malignant cells, thus killing the virus and killing the cancer.
Oncolys, a publicly-traded company on the Tokyo Stock Exchange that also is developing oncolytic adenoviruses, has invested $3 million into Unleash to advance its lead patented programs UIO-512 and UIO-702 toward clinical trials. The programs have already shown promising proof-of-concept results in animal models and human explants.